Life Sciences Archive » September, 2014

Life Sciences - September, 2014

296 articles

• BD Stuck With $114M Antitrust Verdict After New Trial Denied
• Del. High Court Reverses Appriva Investors' $250M Ev3 Win
• Endo Settles 'Substantially All' AMS Vaginal Mesh Claims
• FDA Warns Valeant Over Wrinkle Jab Manufacturing Practice
• 9th Circ. Nixes Challenge To Calif. County's Drug Cleanup Law
• Medical Device Makers See Decline In FDA Discipline
• Novartis' FCA Suit Discovery Request Slammed By States
• Brazilian Vet Products Co. Aims To Fetch $148M In IPO
• SEC Accuses Two Of Illegal Tips On Ackman's Herbalife Bet
• And Now A Word From The Panel: ABCs Of JPML Practice
• ACA Database Shows Pharma Paid $3.5B To Docs, Hospitals
• $1.8B Alios Sale Marks Latham's 2nd Major Deal This Week
• AbbVie CEO Says New Rules Won't Derail $54B Shire Inversion
• Dealmakers Q&A: O'Melveny's Jennifer DePalma
• Drug-Device Applecart Upset Again
• Onyx Traders Can't Kill SEC's $4M Insider Trading Suit
• Products Cases To Watch As Supreme Court Term Kicks Off
• Jurors Can Hear About MDL In DePuy Hip Implant Bellwether
• Bankrupt Vitamin Maker Natrol Aims For Nov. Auction
• Kahn Swick Fights To Keep Abbott Fee Suit In State Court
• Medtronic Can't Shake Investors' Claims Of Tainted Studies
• Cos. Try To Nix More Experts In Nexium Pay-For-Delay Suit
• Atty Sues St. John's For Cut Of Patent Royalty Settlement
• Becton Dickinson Gets Catheter Patent Nixed In AIA Review
• The 4 Firms In-House Counsel Fear The Most
• Lipitor Plaintiffs Admit Pay-For-Delay Suit Doomed
• GlaxoSmithKline Settles Bias Claim By Male Sales Manager
• Takeda Expert Says Smoking Key In Actos Plaintiff's Cancer
• 3 Things To Know As Inversion Rules Muddle Medtronic Deal
• Fed. Circ. Upholds AllPure Win In Millipore Patent Suit
• Pressure Builds On FDA To Overhaul Guidance Process
• Good News For Originators Of Antibody Products
• Allergan Again Blasts Valeant Bid As Investors Urge Talks
• Are NY Practitioners, Pharmacies Ready For E-Prescribing?
• Brothers Still Can't Duck Chattem Insider Trading Verdict
• Chancery Allows Early Appeal In $255M Cornerstone Deal Suit
• Preemption Trend Favors Pharma In Generic Reglan Fight
• Pa. Superior Court Won't Rehear $10M Motrin Verdict
• Rare Arrest Warrant In WL Gore Chancery Case Sent National
• Deals Rumor Mill: AbbVie, ZF Friedrichshafen, T-Mobile
• Biotech Surge Continues With Coherus Filing For $86M IPO
• 1st Amendment Looms Large Over FDA's Twitter Rules
• DC Circ. Knocks FDA's Backtrack On Knee Implant Approval
• Dealmakers Q&A: Phillips Lytle's Asaf Hahami
• Dealmakers Q&A: Saul Ewing's David Antzis
• Investor Slams 'Hostile' Allergan Actions, Urges Deal Talks
• Standard Social Media Practices Are Risky For Big Pharma
• Drug Software Co. Loses Calif. Bid To Duck Warning Suit
• Abbott Labs Wins Nix Of RICO Claims In Humira, AndroGel Suit
• Judge Won't Exclude Experts In Nexium Pay-For-Delay Trial
• Judge Nixes Ohio Willow Patent For Inequitable Conduct
• Cephalon's Patent Experts Barred In FTC Pay-For-Delay Suit
• Genzyme Sues To Stop Generic Leukemia Drug Application
• FDA To Allow More Input Amid Informed Consent Uproar
• Enzo Pays $3.5M To End FCA Medicare Billing Suit
• Allergan Snubs Valeant's Olive Branch, Hints At Other Deal
• Dealmakers Q&A: WilmerHale's Stuart Falber
• Pfizer, AstraZeneca Deal Hopes Wilt After Inversion Rules
• FOIA Is Not Freedom For Plaintiffs To Drug Trade Secrets
• Dealmakers Q&A: Proskauer's Richard Zall
• Boston Scientific Owes $308M After Defibrillator Deal Trial
• FDA Gives Ground On Custom Medical Device Policies
• Abbott Buyout Target's Head Tipped Off Ex-Oriole, Feds Say
• Vertex, Gilead Want Poached-Worker Suit Axed After Deal
• NuVasive's 'Neurovision' Marks Axed As $30M Verdict Upheld
• FDA Eyes Cybersecurity Campaign On Medical Technology
• Reckitt Benckiser Takes Fight Over Suboxone Patent To NJ
• Ontario Gov't Pays $59M To Up Stake In Toronto Tower
• Actavis Seeks Access To NY AG's Files In Antitrust Case
• Nexium Buyers Fight Bid To Nix Experts In Pay-For-Delay Trial
• Chinese Pharma Co. Ducks Investor Suit Over Botched Sale
• Shire Inks $56.5M FCA Settlement Over Adderall Marketing
• Market Rumors: Naturhouse, Emaar Properties, Mercuria
• FDA Email Spying Suit Can't Skip Admin Review, Court Says
• Valeant Asks Allergan To Open Talks, Tone Down Buyout Fight
• Ex-Atty Who Committed Fen-Phen Fraud Gets 20 Years
• FDA Outlines Reforms Of Drug Safety Controls
• Kind Bar Maker, Vitamin Co. Settle Suit Over 'Kind' Marks
• Stiefel Escapes Bid For New Trial In $2M Securities Suit
• Accutane MDL Judge Tosses Roche Warning Label Suit
• Titan Of The Plaintiffs Bar: Daniel Berger
• Generics Lobby Threatens Suit Over FDA Warning Labels Plan
• GNC, USPlabs Settle Class Action Over Recalled Supplements
• Pa. Senate Committee Advances Medical Marijuana Bill
• Canadian Antitrust Chief Vows To Tackle Pay-For-Delay Deals
• Goldberg Segalla Adds Product Liability Attys To Philly Office
• Opportunities And Pitfalls In The Legal Cloud
• Invasion Of The Unannounced EU Notified Body Auditors
• Ackman Threatens To Sue Allergan Over Potential Salix Deal
• Dealmakers Q&A: Butler Snow's James Lawless
• Hospira Can't Kill Epinephrine False Ad Suit, Par Says
• Male Sex Enhancement Pill Maker Can't Escape False Ad Suit
• Valeant Wins Access To Allergan Docs In Insider Trading Row
• Covington Atty Seeks To Escape Subpoena In Nexium MDL
• Life Science Groups Chide CMS Over Sunshine Data Context
• FDA Twitter Rules Unconstitutional, Big Pharma Says
• Cohen Milstein Wrongly Handed Police Powers: Drugmakers
• Kelley Kronenberg Turns Focus To Medical Marijuana In Fla.
• Fleming Nolen Accuses 2 Firms Of Fen-Phen Deal Conspiracy
• CORRECTED: Par Pays $100M To Settle Suit Over Generic Heartburn Drug
• Red-Hot Life Sciences Sector A Skadden M&A Showcase
• Pfizer Pushes To Ax Rest Of Lipitor Pay-For-Delay Suit
• Merck Inks $17B Deal To Broaden Chemicals Business
• Auxilium Spurns $2.2B Endo Bid, Sticks To Acquisition
• Dealmakers Q&A: Epstein Becker's Kevin Ryan
• Purple Is The New Orange: A New Book On Biosimilars
• A General Counsel's Top 10 Billing Tips
• Full Fed. Circ. Won't Eye 'Mandate Rule' In Becton IP Case
• Biotechs Brave Market As Historic IPO Grabs Spotlight
• Merck, BMS Circling Deal With Cipla Over Sustiva Generic
• HHS Watchdog Warns Of Coupon Kickbacks In Part D
• FDA Chides Cipher Over Drug Ad's Superiority Claims
• Citing Lexmark, Drug Co. Says Bayer Couldn't Cancel Mark
• Allergan Defends Redactions In Valeant Insider Trading Suit
• Bill Exposes Drug Cos. To Suits For Abusing Safety Controls
• FCA Free Speech Defense Tested In DOJ-PhRMA Fight
• Criminal Division Wants In On FCA Whistleblower Complaints
• GSK Fined Record $489M For Bribery In China
• Dealmakers Q&A: Crowell & Moring's Bryan Brewer
• New, Final DEA Drug Disposal Rules Are Shady On Details
• Dealmakers Q&A: Nelson Mullins' Brian Moore
• ProQR Prices IPO At $102M Despite Other Biotech Flops
• Takeda Hid Actos Bladder Cancer Risks, Philly Jury Hears
• Testosterone Booster False-Ad Row Survives Dismissal Bid
• White House Gears Up To Combat Drug-Resistant Bacteria
• Medtronic Pays States To Settle Defibrillator FCA Claims
• FDA Panel Targets Testosterone Therapy Risks
• Eli Lilly Slams NY Cymbalta Suit As Possible MDL Looms
• Bayer To Spin Off $10B Polymer Biz In Public Listing
• TAA Case Is Study On Contractors' FCA Vulnerability
• Generics Need Sword, Shield For 'Exceptional' Patent Case
• Pa. High Court Nixes Teva Appeal In Reglan Preemption Fight
• DePuy Exec Defends Hip Implant Success Rate In Texas Trial
• DLA Piper Adds Ex-Pfizer Asia Ace To NY Office
• DOJ Urges FCA Attys To Aid Criminal Fraud Cases
• Valeant Slams Allergan Doc Redactions In Insider Trading Row
• Reckitt Says Suboxone 'Product-Hopping' Didn't Harm Buyers
• Avax Must Pay $5.8M For Breached Cancer Vaccine Contract
• Supplement Makers Pay $3M To End Joint Health False Ad Suit
• Catheter Maker Blasts Ivera's 'Intimidation' In IP Suit
• Judge Knocks Irell For Deposition Tactics In Patent Fight
• Mentor Investors' Appeal Over $1.1B J&J Sale Tossed
• Finnegan Withdraws As Counsel In Hepatitis C Drug IP Row
• Siga Technologies Blames Ch. 11 On Appeal Bond
• Auxilium Takes Poison Pill After $2.2B Endo Offer
• Activist Hedge Fund Wants DuPont Split Into 2 Cos.
• AIA Section 102 — Simplified
• AbbVie Investor Aims To Skunk $54B Shire Inversion
• FDA Clears Up 'Refuse To Receive' Rules For Generics
• Sullivan & Cromwell Reps Endo In $2.2B Auxilium Offer
• NY Antitrust Suit Tests Key Tactic Of Brand-Name Drugmakers
• CSC Unit Seeks $19M Over Botched US Vaccine Contract
• Fed. Circ. Nixes Boston Scientific Appeal In Stent IP Case
• Fla. Medical Marijuana Plan Faces Challenge From Nursery
• 'Male Performance' Supplement Is No Aphrodisiac, Suit Says
• Shire Sues CorePharma Over Plans For Generic Adderall
• Siga Files Ch. 11 After Losing Rival's Botched-Merger Suit
• Deal Makers Start Week With A Multibillion-Dollar Bang
• Novartis Sues Generics Maker Over Organ Rejection Drug
• Teva Again Tells High Court To Nix Claim Construction Rule
• Allergan Compromises With Valeant, Ackman On Meeting
• Post-Nautilus Most Indefinite Patent Challenges Fail
• NY AG Attacks Actavis' Plan To Force New Drug On Patients
• $73M Mesh Verdict Shows Email Evidence's Sway Over Jurors
• Ameritox's Drug-Test Cup Injunction Bid Falls Short
• Teva, AstraZeneca Want Expert Nixed From Nexium Trial
• NJ Mass Torts Relocated Out Of Atlantic County
• Fed. Circ. Won't Consider Sales Ban On Generic Latisse
• Payment Service Owner Cleared In Illegal Pharmacy Case
• Gilead, Indian Generic Cos. Reach Deals Over Hep C Drug
• ACE Won't Pay Amerisource's Attys' Fees After Pa. Appeal
• Alibaba To Overshadow Debuts Of 6 Health Care Cos.
• Ex-CEO Of Diagnostics Co. Alere Unveils $3.8B Buyout Plan
• Life Tech, Illumina Settle DNA Patent Row
• Walgreen Blasts 'Chutzpah' Of Attys' Fee Bid In Pfizer MDL
• Skadden Reps Danaher In $2.2B Nobel Biocare Purchase
• Takeaways For Generics After Octane And Highmark
• OPINION: Why Didn't McDonnell Plead Guilty?
• UK Floats Tighter Takeover Regs After Pfizer-AstraZeneca Bid
• Dealmakers Q&A: Ice Miller's Ed Braum
• Millennium Wins Bid to Reduce Damages in Ameritox Suit
• Pfizer Sheds Lipitor Buyers' Class Action In Antitrust MDL
• Glanbia Drops $153M For Isopure To Bulk Up Supplement Biz
• Chancery Won't Cancel Trial In Allergan Fight With Ackman
• Pfizer's Testosterone Drug Poses Heart Risks, Suit Says
• Kilpatrick Helped Client Steal Confidential IP, Suit Says
• OPINION: Pro Bono May Help Diversity Recruiting Efforts
• Twitter Not Off-Limits For Pharma, FDA Promo Chief Insists
• Bayer Dietary Supplement Ads Violate Court Order, US Says
• Suit Over Fatal Meningitis Outbreak Hits Health Providers
• Reed Smith Atty Widow Settles Subpoena Row With GSK
• J&J Unit, Bayer Want Xarelto Suit Shipped Out Of Philly
• Epstein Becker Green Adds Ex-Paul Hastings Health Care Ace
• 2nd Circ. Limits Monopolist Duty To Deal With Competitors
• Novartis Whistleblower Trims FCA Claims Against CVS
• Pharmacist In Meningitis Outbreak Case Pleads Not Guilty
• Suspect Arrested In Boston Scientific Atty's Shooting Death
• 11th Circ. Tells Fixodent Zinc Plaintiffs To Forget It
• Abbott Announces $3B Share Buyback, Quarterly Dividend
• J&J To Face Suit Over Allegedly Misleading Sunscreen Labels
• Ackman's Investor Support Tips Allergan Meeting Fight
• High-Profile Hostile Plays Reinforce Bright M&A Outlook
• FCA Whistleblowers Accuse Gilead Of Defective-Drug Fraud
• Nordion Says 11th Circ. Misapplied Test To Fla. Contract
• SEC Settles Heart-Monitoring Co.'s Stock-Inflation Case
• Lorillard Loses Appeal Of $45M Engle Verdict
• How Research Efficiency Impacts Law Firm Profitability
• What FTC Is Saying In 1st Post-Actavis Pay-For-Delay Case
• 5 Insights From Ford General Counsel David Leitch
• FDA Flouted 'Plain Meaning' Of Device Law, Judge Rules
• Insurer Off Hook For Defective Titanium Deal, NJ Court Says
• FDA Tells Compounder To Recall Contaminated Goods Again
• Cornerstone Directors Can't Escape Suit Over $255M Buyout
• Advanced Cell Settles SEC Claims Over CEO's Hidden Trading
• Fed. Claims Axes Health Co.'s Contract Over Supplier Status
• Regenerative Med Co. Says Ex-Employees Stole Trade Secrets
• NRDC Urges 2nd Circ. To Rehear Livestock Antibiotic Suit
• Lilly Opposes Creating MDL For Cymbalta 'Brain Zap' Suits
• JFTC Joins Regulatory Probes Of $13.4B Zimmer-Biomet Deal
• At The ITC, Even The Rulemaker Has To Follow The Rules
• Best Business Planning Practices For Lawyers
• 11th Circ. Won't Rehear Stiefel Appeal In $1.5M Share Fight
• PhRMA Fires Back At Feds In FCA Off-Label Suit
• 3rd Circ. Asked To Revive Genaera 'Fire Sale' Investor Row
• Lidoderm Buyers Fight Dismissal Bid In Pay-For-Delay Suit
• Chicago Fights Bid To DQ Cohen Milstein In Painkiller Suit
• Boston Sci Hit With $73M Verdict In 1st Pelvic Mesh Loss
• Class Suit Accuses Enzymotec Of Lying Before Its $70M IPO
• FDA Defends Lab Test Oversight Before Critical Lawmakers
• Goodwin Procter Snags Five-Atty IP Team From Kenyon
• 2nd Circ. Ruling May Spark More Lanham Act Cases
• Dealmakers Q&A: Sills Cummis' Ira Rosenberg
• When Inter Partes Review Meets Hatch-Waxman Patents
• State Claims Trimmed From AbbVie, Teva Pay-for-Delay MDL
• FTC Targets AbbVie, Teva In 1st New Pay-For-Delay Suit
• Aussie Court OKs Myriad Gene Patents, Knocks US High Court
• Lilly Funds Suit Against CMS Over Alzheimer's Test
• Allergan Can't Duck Class Action Over Cream Cancer Risks
• 4th Circ. Set Stage For Endless FCA Suits, Justices Told
• Pfizer, Purdue Prevail In Suit Over Settlement Records
• 23andMe Wants Hold On Coverage Suit Amid DNA Test Row
• Hospira Can't Block Generic Precedex, Judge Rules
• Alibaba Steals Spotlight As Fall US IPO Market Heats Up
• FDA Must Grant Depomed's Pain Drug Exclusivity, Judge Says
• Indian Watchdog Questions $3B Sun Pharma-Ranbaxy Deal
• Brand Battles: Samsung, Actavis, Hyundai
• Accentia Strikes $1.25M Deal To End Investors' Vaccine Suit
• Unions Aim To Bar Health Programs From Trade Deal Fights
• Antitrust, FCA Claims On Merck Mumps Vaccine To Advance
• Merck Ordered Into Mediation In Fosamax Litigation
• Boston Scientific Whistleblowers Can't Duck Counterclaims
• Costco, Apotex Sued Over Sales Of Imported Lipitor Generic
• Novartis Can't Escape FCA Drug Kickback Suit
• Hughes Hubbard Snags 2 Fried Frank Patent Partners In NY
• J&J's Ethicon Hit With $3.27M Verdict In Pelvic Mesh Trial
• Allergan OKs Shareholder Meeting In Win For Valeant, Ackman
• Biosimilar Patent Disputes: What Sandoz Appeal May Clarify
• Precedex Decision Will Impact FDA's Use Code System
• Dealmakers Q&A: Ropes & Gray's Matthew Richards
• 5 Insights From AT&T General Counsel Wayne Watts
• J&J, Ethicon Seek Early Win At Bellwether Pelvic Mesh Trial
• Loestrin Pay-For-Delay Case Can't Survive Actavis, Judge Says
• Document Storage Tips: Inside The Email Vault
• Forest Labs Sues Sigmapharm To Halt Generic Antipsychotic
• Hyman Phelps Says Baxter's HyQvia Needs Strict Labeling
• Daiichi Sankyo Targeted Worker In Retaliation, Suit Says
• Vaccine Investors Can't Exploit Tax Credit, UK Court Says
• PharMerica Can't Trim FCA Suit Over Painkiller Prescriptions
• Top NY Court Rejects Forest Lab Bid For Coverage From RSUI
• Ex-Va. Gov. McDonnell, Wife Found Guilty Of Corruption
• Pharmacist In Meningitis Outbreak Case Arrested At Airport
• Forest Asks 1st Circ. To End Lexapro Marketing Class Action
• Innovator Liability Finds Sweet Home In Ala.
• Deals Rumor Mill: Hospira, Pioneer, Bombardier
• Nautilus, Biosig Spar Over High Court Indefiniteness Ruling
• Hunt Continues For Boston Scientific Atty Shooter
• Smith & Nephew To Pay $8M To Settle FCA Suit With VA
• Clinic Owner Tied To MLB Doping To Plead Guilty In Oct.
• 4 Biotechs Set Terms As US IPO Market Braces For Surge
• Reed Smith Atty's Calls May Shed Light On Suicide, GSK Says
• FTC Promotes Attys Who Scrutinized ProMedica, Thermo Deals
• J&J, Boston Sci Can't Nix Pelvic Mesh Injury Claims En Masse
• Ranbaxy Fights Doc Bid In Nexium Pay-For-Delay Fight
• No Word From Pfizer, AstraZeneca As Deal Chatter Tapers
• The Glass Slipper: Searching For The FCA Case That Fits
• Pot Stock Puffery And Regulating An Illicit Industry
• Hi-Tech Execs Ordered To Jail For Contempt Of Recall Order
• Drug Cos. Call Chicago's Painkiller Marketing Suit Unwieldy
• Judge Favors Par In Novartis Alzheimer's Patch Patent Row
• Boehringer Sues Mylan To Block Generic Aggrenox
• Pfizer Ducks Zoloft False-Ad Claims In Calif.
• Allergan Must Face Suit Over Botox Labeling: 9th Circ.
• Vitamin Shoppe Sued Over Supplement False Labeling
• Allergan Hits Back After Valeant Stands By Business Model
• Dealmakers Q&A: Gray Plant's Mark Williamson
• Framing The Naming Debate For Biosimilars